Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AVEO Pharmaceuticals Inc is a biotechnology business based in the US. AVEO Pharmaceuticals shares (AVEO) are listed on the NASDAQ and all prices are listed in US Dollars. AVEO Pharmaceuticals employs 114 staff and has a trailing 12-month revenue of around $79 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $8.14 |
|---|---|
| 52-week range | $3.06 - $9.37 |
| 50-day moving average | $7.75 |
| 200-day moving average | $5.46 |
| Wall St. target price | $15.60 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.14 from 2022-09-29
| 1 week (2022-09-23) | 5.03% |
|---|---|
| 1 month (2022-09-01) | -2.63% |
| 3 months (2022-07-01) | 21.31% |
| 6 months (2022-03-31) | 45.62% |
| 1 year (2021-10-01) | 29.82% |
|---|---|
| 2 years (2020-10-01) | 37.27% |
| 3 years (2019-10-01) | 880.49% |
| 5 years (2017-09-29) | 123.01% |
| Revenue TTM | $79 million |
|---|---|
| Gross profit TTM | $11.3 million |
| Return on assets TTM | -18.68% |
| Return on equity TTM | -79.61% |
| Profit margin | -45.72% |
| Book value | $0.88 |
| Market capitalisation | $281.4 million |
TTM: trailing 12 months
We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months.
AVEO Pharmaceuticals's shares were split on a 1:10 basis on 19 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for AVEO Pharmaceuticals shares which in turn could have impacted AVEO Pharmaceuticals's share price.
Over the last 12 months, AVEO Pharmaceuticals's shares have ranged in value from as little as $3.06 up to $9.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 0.7535. This would suggest that AVEO Pharmaceuticals's shares are less volatile than average (for this exchange).
AVEO Pharmaceuticals, Inc. , an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc. ; CANbridge Life Sciences, Ltd.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.